Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with New Therapeutic Equivalence Data Presented at British Thoracic Society (BTS) Winter Meeting
November 26, 2025 – –
Parma, Italy – 26 November 2025 – Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announced new data presented at the British Thoracic Society (BTS) Winter Meeting. The findings confirm that Chiesi’s beclometasone dipropionate/formoterol fumarate product formulated with hydrofluoroalkane (HFA) 152a, delivers comparable clinical efficacy and safety to the currently marketed formulation using HFA-134a1.
Pressurised metered dose inhalers (pMDIs) account for around 0.1% of global greenhouse gas emissions3 – a proportion expected to rise as other sectors reduce emissions, highlighting the need for timely action4,5. Importantly, more than 85% of patients and carers support the move to sustainable inhalers, provided therapeutic outcomes remain uncompromised6,7.
“This announcement underlines our commitment to reducing the environmental impact of respiratory care without compromising clinical performance.” said Carmen Dell’Anna, Senior Vice President Global Medical Affairs & Franchise Air Strategy. “Ensuring our carbon minimal pMDI portfolio deliver a comparable trusted efficacy and safety as current products, will help healthcare professionals guide a seamless transition for patients, maintaining continuity of care while advancing sustainability.”
Chiesi’s Carbon Minimal Inhaler program is a key driver of a broader ambition to achieve Net Zero greenhouse gas emissions by 2035, strengthening its leadership in sustainable innovation that delivers benefits for patients and the planet.
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By adopting the legal form of Benefit Corporation in Italy, the US, France, and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
